NYSEAMERICAN:SER Serina Therapeutics Q4 2025 Earnings Report $2.09 -0.05 (-2.34%) Closing price 09/25/2026 04:10 PM EasternExtended Trading$2.13 +0.04 (+1.96%) As of 09/25/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Serina Therapeutics EPS ResultsActual EPS-$0.31Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASerina Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASerina Therapeutics Announcement DetailsQuarterQ4 2025Date3/25/2026TimeAfter Market ClosesConference Call DateWednesday, March 25, 2026Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Serina Therapeutics Earnings HeadlinesSerina Therapeutics - Registration Is Now Open for Tribe Public's CEO Presentation and Q&A Webinar Event 'A New Approach to Advanced Parkinson's disease: Serina Discusses SER ...September 24 at 12:02 PM | marketscreener.comMRegistration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical ...September 23 at 9:00 PM | markets.businessinsider.comAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared.September 26 at 1:00 AM | Stansberry Research (Ad)Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"September 23 at 4:18 PM | globenewswire.comSerina Therapeutics op H.C. Wainwright-conferentie: vooruitgang in Parkinson-programmaSeptember 11, 2026 | nl.investing.comSerina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | globenewswire.comSee More Serina Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Serina Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Serina Therapeutics and other key companies, straight to your email. Email Address About Serina TherapeuticsSerina Therapeutics (NYSEAMERICAN:SER) is a clinical-stage biotechnology company developing medicines for chronic diseases. The company uses its proprietary POZ polymer technology to modify therapeutic molecules with the goal of extending their duration of action, potentially reducing dosing frequency and improving treatment convenience. Serina’s lead product candidate is SER-252, also known as POZ-apraglutide, a long-acting version of the peptide apraglutide. The company is evaluating the candidate as a potential treatment for short bowel syndrome with intestinal failure and other conditions in which enhanced intestinal absorption may be beneficial. The company’s development programs are based on its POZ platform, which is designed to control the release and circulation of attached drug compounds. Serina Therapeutics is headquartered in Huntsville, Alabama, and its pipeline remains focused on advancing long-acting therapies through clinical development.View Serina Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
